GlaxoSmithKline in $1.5 billion collaboration deal

Share this article:
GlaxoSmithKline announced a deal on Thursday with the privately held drug research firm ChemoCentryx to discover, develop and market novel medicines for a variety of inflammatory disorders. As part of the deal ChemoCentryx will receive an upfront payment of $63.5 million and will be eligible to earn milestone payments up to, potentially, $1.5 billion. Under the agreement, Mountain View, CA-based ChemoCentryx will also get a double digit royalty percentage on collaboration product sales, and an investment from GlaxoSmithKline should the company go public. ChemoCentryx's Traficet-EN, which is in late stage development for the treatment of inflammatory bowel disease, is included in the agreement.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.